A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Conditions: Healthy Participants; Atopic Dermatitis Patients Interventions: Drug: IBI356 for MAD; Drug: Dupilumab for MAD; Drug: IBI356 for SAD; Drug: Placebo for SAD; Drug: Placebo for MAD Sponsors: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials